Aevi Genomic Medicine — Medgenics — Q3 2016 Earnings Presentation
27 slides from Aevi Genomic Medicine's earnings presentation, Nov 3, 2016
Slide 1: Q3 Business Update and Financials
Q3 Business Update and Financials November 3, 2016
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operating and financial performance, clinical results,
Slide 3: Q3 2016 Executive Summary
Q3 2016 Executive Summary 3 NFC – 1 Programs Advancing – mGluR+ ADHD • Enrollment ongoing; top - line data expected around year end • mGluR + prevalence rate of ~25% confirmed • US market opportunity of $ 2B – $3B – 22q Deletion Syndrome • Study initiated at CHOP • Initial data expected in H1 2017 A
Slide 4: Genomic Medicine Approach
Genomic Medicine Approach medgenics
Slide 5: Genetic Influence in Pediatric Disorders
Genetic Influence in Pediatric Disorders E arly Onset Disease: Distinct genetically driven Severe burden of illness Aggressive progression Less responsive to standard of care 5 *1Ruel, J. et al. (2013) IBD across the age spectrum — is it the same disease? Nat. Rev. Gastroenterol . Hepatol . doi:10.1
Slide 6: Center for Applied Genomics (CAG) at CHOP
Center for Applied Genomics (CAG) at CHOP CAG’s pediatric biobank contains a high percentage of rare genetic variants Datasets (Genomics EMR) Over 75K pediatric and 150K related adult patients GWAS genotyped with associated longitudinal EMR since 2006 Data Analytics End to end internal Next - Gen se
Slide 7: CAG/MDGN - Genetic Discoveries to Drugs
CAG/MDGN - Genetic Discoveries to Drugs 7 Genomically Validated Target Rational Search & Acquisition Genomically Guided Product Development Targeted Launch Medgenics ’ R ole: Match unique genetic discoveries with potential therapies Acquire the rights to programs that have been abandoned – Ideal pro
Slide 8: Benefits of Genomic Guided Drug Development
Benefits of Genomic Guided Drug Development Higher Value Medicines Improved response rates Smaller, faster, clinical trials Increased probability of regulatory success Targeted launch Potential label expansion in adjacent genetic diseases G enomic biomarkers improve overall program outcomes 8
Slide 9: NFC-1 Program Update
NFC-1 Program Update medgenics
Slide 10: ADHD: Rationale for Genomic Medicine Approach
ADHD: Rationale for Genomic Medicine Approach Most prevalent neurodevelopmental disorder in children Highly heritable* (70%); Heterogeneous, suggesting multiple causes Early studies focused on individual genes failed to identify causal associations N ovel discovery from CAG, based on network biology
Slide 11: mGluR Mutations Highly Predictive of ADHD
mGluR Mutations Highly Predictive of ADHD 11 In a blinded study of 155 mGluR+ patients assessed in CHOP psychiatry > 98% were diagnosed with ADHD H. Hakonarson , data presented at 63rd Annual American Academy of Child and Adolescent Psychiatry in Oct 2016
Slide 12: NFC-1: ADHD Program
NFC - 1: ADHD Program 12 ADHD Phenotype / Genotype Pediatrics, Adolescents N=1,000+ Design: Non - interventional Multi - center (25) Genotype 1,000+ ADHD subjects, age 6 - 17, identifying patients who are mGluR + Phase 2/3 mGluR+ ADHD, Adolescents N=90, Ages 12 - 17 Phase 3 mGluR+ ADHD, Pediatrics N
Slide 13: Mutation Prevalence Confirmed in Phenotype/Genotype Study
Mutation Prevalence Confirmed in Phenotype/Genotype Study 13 Data presented at 63 rd Annual American Academy of Child and Adolescent Psychiatry Meetings (AACAP) in Oct 2016 Age Group mGluR+ (n) Total (n) % Pediatrics (ages 6 - 12) 71 271 26% Adolescents (ages 13 - 17) 271 1,274 21% A ddressable pedi
Slide 14: mGluR+ ADHD Patients: Higher Prevalence of Negative Symptoms
mGluR+ ADHD Patients: Higher Prevalence of Negative Symptoms (n=1013) 14 In mGluR+ patients*: • Symptoms associated with emotional dysregulation most prominent: disruptive behavior, anger control • Emotional dysregulation often has significant life consequences** • Majority of symptoms more prevalen
Slide 15: "Fail First" Treatment Paradigm in ADHD
• Current diagnostic paradigm is symptom - based without objective biomarkers • Current treatment paradigm exposes children to multiple stimulants in a “fail first” approach • Underlying safety concerns create issues with compliance and adherence: • Cardiovascular risk • Growth retardation • Sleep d
Slide 16: NFC-1: Potential for Superior Product Profile
NFC - 1: Potential for Superior Product Profile NFC - 1 clinical profile in mGluR+ ADHD patients – Effective non - stimulant (non - scheduled) – Excellent safety profile in >1,000 patients No evidence of growth retardation, addiction, sleep disturbance No evidence of cardiovascular risk No expectati
Slide 17: mGluR+ ADHD: Market Opportunity
mGluR + ADHD: Market Opportunity Overall US ADHD Market – 2015 Sales in excess of $10B* – ~6M pediatric / adolescent patients** – Stimulants dominate market: 90+% of total prescriptions mGluR + ADHD Market, ages 6 - 17 – 1.2M - 1.5M patients (~25% mGluR+) – $ 2B - $3B market opportunity based upon c
Slide 18: Anti-LIGHT mAb Program
Anti-LIGHT mAb Program ta medgenics
Slide 19: Anti-LIGHT mAb Program
Anti - LIGHT mAb Program First - in - Class Biologic from Kyowa Hakko Kirin – Initial development in S evere P ediatric O nset IBD – Phase 2 ready antibody – Strong regulatory e xclusivity and robust i ntellectual p roperty p ortfolio – High value c ommercial o pportunity with potential for indicati
Slide 20: Rationale for Anti-LIGHT Approach
Rationale for Anti - LIGHT Approach DcR3 is strongly linked to Severe Pediatric Onset IBD 1 Initial strategy to augment DcR3 – Very short half life – Toxicity reported with previous DcR3 analog “Rational Search” based on biological pathway – LIGHT overexpressed in IBD – DcR3 LOF increases LIGHT 2 20
Slide 21: Rapid Development Pathway to Approval
Rapid Development Pathway to Approval 21 Severe Pediatric Onset IBD POC Trial Anticipated Phase 1b design: Single center (CHOP) N = up to 12 patients Duration 8 weeks Ascending dose Endpoints : Endoscopic Evaluation, Crohn’s Disease Activity Index (CDAI ), Safety Estimated Cost: ~$2M Single Phase 3
Slide 22: Severe Pediatric Onset IBD: Top Down Treatment Paradigm
Severe Pediatric Onset IBD: “ Top Down” Treatment Paradigm 22 1 Altwegg & Vincent (2014) TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease. Mediators of Inflammation. doi:10.1155/2014/172821 Treatment Objectives : Induce remission with anti - TNFα immediately so
Slide 23: Severe Pediatric Onset IBD: Anti-LIGHT Opportunity
Severe Pediatric Onset IBD: Anti - LIGHT Opportunity (US Pop.) 23 1 Kappleman et al. (2007) Clin Gastro Hepat 2 Oliva - Hemker (2015) J Pedtr 3 Remicade Monograph 4 Altwegg - Vincent (2014) Mediators of Inflamm Initial Target: anti - TNFα failure with DcR3 Loss of Function 2,000 – 3,000 IBD patients
Slide 24: Financials & Milestones
Financials & Milestones ta medgenics
Slide 25: Q3 2016 Financial Update
Q3 2016 Financial Update R&D expenses for the 3 rd Quarter were $7.7M (gross) and $7.5M (net), increasing from $4.6M (gross) and $4.2M (net) for the same period in 2015 – Primarily due to increased spend on clinical activities related to advancing the NFC - 1 (MDGN - 001) program G&A expenses for th
Slide 26: Upcoming Milestones
Upcoming Milestones 26 R&D Programs Timing NFC - 1 Complete enrollment in phenotype / genotype study ✓ Initiate enrollment in Phase 2/3 mGluR+ ADHD Adolescent Trial ✓ Top line data H2 16 Initiate enrollment in Phase 1/2 22q Deletion Syndrome Trial Q4 16 Initial open - label responder data H1 17 Anti
Slide 27: medgenics
medgenics